{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:48:57Z","timestamp":1773006537070,"version":"3.50.1"},"reference-count":90,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Gastric cancer (GC) is the third leading cause of cancer-associated death worldwide. The majority of patients are diagnosed at an advanced\/metastatic stage of disease due to a lack of specific symptoms and lack of screening programs, especially in Western countries. Thus, despite the improvement in GC therapeutic opportunities, the survival is disappointing, and the definition of the optimal treatment is still an unmet need. Novel diagnostic techniques were developed in clinical trials in order to characterize the genetic profile of GCs and new potential molecular pathways, such as the Fibroblast Growth Factor Receptor (FGFR) pathway, were identified in order to improve patient\u2019s survival by using target therapies. The aim of this review is to summarize the role and the impact of FGFR signaling in GC and to provide an overview regarding the potential effectiveness of anti-FGFR agents in GC treatment in the context of precision medicine.<\/jats:p>","DOI":"10.3390\/life12010081","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T20:21:56Z","timestamp":1641759716000},"page":"81","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-516X","authenticated-orcid":false,"given":"Csongor G.","family":"Lengyel","sequence":"first","affiliation":[{"name":"Head and Neck Surgery, National Institute of Oncology, 1122 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaqat","family":"Hussain","sequence":"additional","affiliation":[{"name":"Oncology Department, University Hospital of Leicester, Leicester LE1 5WW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-7824","authenticated-orcid":false,"given":"Andreas","family":"Seeber","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Innsbruck, Department of Hematology and Oncology, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Jamil Nidhamalddin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hiwa Cancer Hospital, Sulayamaniyah 46001, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[{"name":"European Institute of Oncology, 20141 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8070-8532","authenticated-orcid":false,"given":"Baker S.","family":"Habeeb","sequence":"additional","affiliation":[{"name":"Medical Oncology, Shaqlawa Teaching Hospital, Erbil 44001, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essam","family":"Elfaham","sequence":"additional","affiliation":[{"name":"Department of Hematoncology, Kuwait Cancer Control Center (KCCC), Kuwait City 20001, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Ayub","family":"Mazher","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, UT Southwestern Clements University Hospital, Dallas, TX 75390, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4983-890X","authenticated-orcid":false,"given":"Fahmi","family":"Seid","sequence":"additional","affiliation":[{"name":"Department of Oncology, College of Medicine and Health Sciences, Hawassa University, Hawassa 1560, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3692-6150","authenticated-orcid":false,"given":"Shah Z.","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, BINOR Cancer Hospital, Bannu 28000, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8414-4145","authenticated-orcid":false,"given":"Khalid","family":"El Bairi","sequence":"additional","affiliation":[{"name":"Cancer Biomarkers Working Group, Oujda 60000, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7275-2186","authenticated-orcid":false,"given":"Andrew","family":"Odhiambo","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology, Department of Clinical Medicine, University of Nairobi, Nairobi 00202, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara C.","family":"Altuna","sequence":"additional","affiliation":[{"name":"Oncom\u00e9dica C. A., Caracas 1040, Venezuela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-5733","authenticated-orcid":false,"given":"Angelica","family":"Petrillo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale del Mare, 80147 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11894-017-0575-8","article-title":"Changing Trends in Stomach Cancer throughout the World","volume":"19","author":"Balakrishnan","year":"2017","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/ijc.30835","article-title":"Global patterns and trends in stomach cancer incidence: Age, period and birth cohort analysis","volume":"141","author":"Luo","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2468-1253(19)30357-7","article-title":"27 years of stomach cancer: Painting a global picture","volume":"5","author":"Petrillo","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1053\/j.gastro.2015.05.059","article-title":"Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma","volume":"149","author":"Tan","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc703","article-title":"Helicobacter pylori and gastrointestinal tract adenocarcinomas","volume":"2","author":"Peek","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdr135","article-title":"A meta-analysis on alcohol drinking and gastric cancer risk","volume":"23","author":"Tramacere","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdy502","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO\u2013ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS","volume":"30","author":"Muro","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","first-page":"Cd004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"K\u00f6rfer, J., Lordick, F., and Hacker, U.T. (2021). Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. Cancers, 13.","DOI":"10.3390\/cancers13205216"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202\u2013209.","DOI":"10.1038\/nature13480"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1038\/s41388-021-01840-3","article-title":"Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"ref_14","first-page":"1319","article-title":"Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma","volume":"23","author":"Salem","year":"2018","journal-title":"Oncology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Bang","year":"2015","journal-title":"Gastric Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000510489","article-title":"Biomarkers for Precision Treatment in Gastric Cancer","volume":"36","author":"Petrillo","year":"2020","journal-title":"Visc. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gambardella, V., Fleitas, T., Tarazona, N., Papaccio, F., Huerta, M., Rosell\u00f3, S., Gimeno-Valiente, F., Roda, D., and Cervantes, A. (2020). Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. J. Clin. Med., 9.","DOI":"10.3390\/jcm9093049"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"111884","DOI":"10.1016\/j.ejmech.2019.111884","article-title":"Recent advance in the development of novel, selective and potent FGFR inhibitors","volume":"186","author":"Liu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104567","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s11033-020-06094-y","article-title":"Alternative splicing modulates cancer aggressiveness: Role in EMT\/metastasis and chemoresistance","volume":"48","author":"Das","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_23","first-page":"950508","article-title":"Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer","volume":"2012","author":"Holzmann","year":"2011","journal-title":"J. Nucleic Acids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"962962","DOI":"10.1155\/2014\/962962","article-title":"A Network Map of FGF-1\/FGFR Signaling System","volume":"2014","author":"Raju","year":"2014","journal-title":"J. Signal Transduct."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tig.2004.08.007","article-title":"Evolution of the Fgf and Fgfr gene families","volume":"20","author":"Itoh","year":"2004","journal-title":"Trends Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1074\/jbc.M116.755777","article-title":"A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors","volume":"292","author":"Sarabipour","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ferguson, H.R., Smith, M.P., and Francavilla, C. (2021). Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. Cells, 10.","DOI":"10.3390\/cells10051201"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/MCB.20.3.979-989.2000","article-title":"FRS2 Proteins Recruit Intracellular Signaling Pathways by Binding to Diverse Targets on Fibroblast Growth Factor and Nerve Growth Factor Receptors","volume":"20","author":"Ong","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Arkun, Y., and Yasemi, M. (2018). Dynamics and control of the ERK signaling pathway: Sensitivity, bistability, and oscillations. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195513"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fcell.2020.00079","article-title":"FGF Signaling Pathway: A Key Regulator of Stem Cell Pluripotency","volume":"8","author":"Quan","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"188619","DOI":"10.1016\/j.bbcan.2021.188619","article-title":"Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis","volume":"1876","author":"Mandal","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: Biologic and clinical implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"ref_33","first-page":"3893","article-title":"Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing","volume":"11","author":"Gu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.21037\/atm-20-5118","article-title":"A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients","volume":"8","author":"Sun","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10120-017-0758-x","article-title":"In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients","volume":"21","author":"Kuboki","year":"2017","journal-title":"Gastric Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2011.603","article-title":"FGFR2 gene amplification and clinicopathological features in gastric cancer","volume":"106","author":"Matsumoto","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4659062","DOI":"10.1155\/2020\/4659062","article-title":"Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers","volume":"2020","author":"Lee","year":"2020","journal-title":"J. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"55924","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: Mini review","volume":"7","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15014","DOI":"10.18632\/oncotarget.14788","article-title":"Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.7150\/jca.40531","article-title":"FGF\/FGFR signaling pathway involved resistance in various cancer types","volume":"11","author":"Zhou","year":"2020","journal-title":"J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Nienh\u00fcser, H., and Schmidt, T. (2017). Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010043"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR Signaling in Cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors","volume":"26","author":"Facchinetti","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e1916091","DOI":"10.1001\/jamanetworkopen.2019.16091","article-title":"Estimation of Percentage of Patients with Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/1078155220983425","article-title":"Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class","volume":"27","author":"Weaver","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Liu, P.C.C., Koblish, H., Wu, L., Bowman, K., Diamond, S., DiMatteo, D., Zhang, Y., Hansbury, M., Rupar, M., and Wen, X. (2020). INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231877"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"v876","DOI":"10.1093\/annonc\/mdz394.031","article-title":"LBA40\u2014FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1981202","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"mAbs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3892\/ol.2020.11685","article-title":"Anlotinib as a molecular targeted therapy for tumors (Review)","volume":"20","author":"Gao","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"683502","DOI":"10.3389\/fonc.2021.683502","article-title":"Anlotinib Combined with Anti-PD-1 Antibodies Therapy in Patients with Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study","volume":"11","author":"Yuan","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets","volume":"61","author":"Deng","year":"2012","journal-title":"Gut"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc. Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"803","DOI":"10.21037\/apm-20-2572","article-title":"Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: A case report","volume":"10","author":"Wang","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107281","DOI":"10.1016\/j.intimp.2020.107281","article-title":"Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review","volume":"91","author":"Mo","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.117.244129","article-title":"Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases","volume":"364","author":"Hilberg","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1158\/1535-7163.MCT-14-0255","article-title":"Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification","volume":"13","author":"Kim","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e04986","DOI":"10.1002\/ccr3.4986","article-title":"Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma","volume":"9","author":"Limaye","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam, F., Bahleda, R., Hierro, C., Sanson, M., Bridgewater, J., Arkenau, H.-T., Tran, B., Kelley, R.K., Park, J.O., and Javle, M. (2021). Futibatinib, an Irreversible FGFR1\u20134 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF\/FGFR Aberrations: A Phase I Dose-Expansion Study. Cancer Discov.","DOI":"10.1158\/2159-8290.CD-21-0697"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s13277-015-4100-0","article-title":"Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer","volume":"37","author":"Ye","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","article-title":"A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer","volume":"12","author":"Michael","year":"2017","journal-title":"Target. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"113499","DOI":"10.1016\/j.ejmech.2021.113499","article-title":"Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors","volume":"220","author":"Ran","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"633410","DOI":"10.3389\/fonc.2021.633410","article-title":"MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells","volume":"11","author":"Kitowska","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"iv122","DOI":"10.1093\/annonc\/mdz157.002","article-title":"SO-003-Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: Preliminary results","volume":"30","author":"Matos","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_70","first-page":"6655","article-title":"Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model","volume":"35","author":"Schmidt","year":"2015","journal-title":"Anticancer. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10120-014-0444-1","article-title":"Epithelial\u2013mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells","volume":"19","author":"Grygielewicz","year":"2014","journal-title":"Gastric Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1007\/s10620-020-06640-5","article-title":"Knockdown of Bcl-2-Associated Athanogene-3 Can Enhance the Efficacy of BGJ398 via Suppressing Migration and Inducing Apoptosis in Gastric Cancer","volume":"66","author":"Li","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2016.03.068","article-title":"Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models","volume":"61","author":"Tsimafeyeu","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1007\/s13277-015-4411-1","article-title":"The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer","volume":"37","author":"Li","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","article-title":"First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer","volume":"14","author":"Kim","year":"2019","journal-title":"Target Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"14537","DOI":"10.3748\/wjg.v20.i40.14537","article-title":"Clinical management of advanced gastric cancer: The role of new molecular drugs","volume":"20","author":"Fabozzi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/annonc\/mdx107","article-title":"A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification","volume":"28","author":"Bang","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e034685","DOI":"10.1136\/bmjopen-2019-034685","article-title":"Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: Study protocol for a single-armed and single-centred clinical trial","volume":"10","author":"Wang","year":"2020","journal-title":"BMJ Open"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2021.39.3_suppl.160","article-title":"Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric\/gastroesophageal junction adenocarcinoma (FIGHT)","volume":"39","author":"Wainberg","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/JCO.2021.39.15_suppl.4010","article-title":"FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric\/gastroesophageal junction adenocarcinoma (GC)","volume":"39","author":"Catenacci","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Zhang, J., Tang, P.M.K., Zhou, Y., Cheng, A.S.L., Yu, J., Kang, W., and To, K.F. (2019). Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis. Cells, 8.","DOI":"10.3390\/cells8060637"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1535-7163.MCT-20-0836","article-title":"Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK","volume":"20","author":"Lau","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41420-020-0246-7","article-title":"TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer","volume":"6","author":"Zhao","year":"2020","journal-title":"Cell Death Discov."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-017-0592-3","article-title":"Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer","volume":"36","author":"Englinger","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"de Klerk, D.J., Honeywell, R.J., Jansen, G., and Peters, G.J. (2018). Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. Cancers, 10.","DOI":"10.3390\/cancers10120503"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.1204592","article-title":"TFEB Links Autophagy to Lysosomal Biogenesis","volume":"332","author":"Settembre","year":"2011","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/ncb3114","article-title":"Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB","volume":"17","author":"Medina","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3324\/haematol.2009.008631","article-title":"ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug","volume":"94","author":"Chapuy","year":"2009","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/2326-6066.CIR-18-0595","article-title":"The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity","volume":"7","author":"Palakurthi","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2326-6066.CIR-20-0235","article-title":"Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade","volume":"8","author":"Akhand","year":"2020","journal-title":"Cancer Immunol. Res."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/1\/81\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:36:39Z","timestamp":1760362599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/1\/81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["life12010081"],"URL":"https:\/\/doi.org\/10.3390\/life12010081","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]}}}